Issue
Copyright (c) 2026 Elham Mahdavi, Batool Ghorbani Yekta, Fereshteh Atabi

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.The effect of citalopram treatment on memory performance, mood state, catalase, BDNF, and MDA in REM sleep-deprived rats
Corresponding Author(s) : Batool Ghorbani Yekta
Cellular and Molecular Biology,
Vol. 72 No. 2: Issue 2
Abstract
Rapid-eye movement (REM) sleep is a critical stage of sleep that plays a pivotal role in memory formation, consolidation, and mood regulation. While REM sleep deprivation (REM SD) has been shown to impair cognitive and affective functions, findings across studies remain inconsistent. REM SD may also influence the expression of brain-derived neurotrophic factor (BDNF), a key protein involved in memory and mood-related processes. In this study, we investigated the effects of REM SD (6 h/day for 7 days) on behavioral and cognitive performance, BDNF levels in the prefrontal cortex, and serum markers of oxidative stress—catalase (CAT, an antioxidant enzyme) and malondialdehyde (MDA, a lipid peroxidation product). Additionally, we evaluated the potential therapeutic effect of citalopram (20 mg/kg, i.p., for 7 days) on REM SD-induced behavioral deficits. Our results demonstrated that REM SD increased locomotor activity and rearing behavior, impaired passive avoidance memory, and reduced pain threshold. REM SD also downregulated prefrontal BDNF expression but did not alter serum CAT or MDA levels. Citalopram treatment reversed REM SD-induced hyperlocomotion, increased rearing, pain hypersensitivity, and BDNF downregulation; however, it did not significantly improve memory impairment. Depressive-like behavior remained unchanged across groups. These findings suggest that BDNF modulation may underlie both the detrimental effects of REM SD and the therapeutic actions of citalopram, whereas peripheral oxidative stress markers (CAT and MDA) do not appear to play a major role in this paradigm.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX